ロード中...
90 Y-ibritumomab tiuxetan: a nearly forgotten opportunity
Y-ibritumomab tiuxetan (90Y-IT) combines the benefits of a monoclonal antibody with the efficacy of radiation in the treatment of B-cell non-Hodgkin lymphoma (NHL), a remarkably radiosensitive hematologic malignancy. 90Y-IT activity has been well established in the indolent setting, being approved i...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4884941/ https://ncbi.nlm.nih.gov/pubmed/26657116 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6531 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|